Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Zanubrutinib, a Second Generation BTK Inhibitor, in Anti-MAG Antibody Neuropathy: a Phase II Italian Multicenter Clinical Trial (MAZINGA)

NCT07392229 is registered in ClinicalTrials.gov with Azienda Ospedaliera di Padova as lead sponsor.

NCT NCT07392229
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392229 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Zanubrutinib, a Second Generation BTK Inhibitor, in Anti-MAG Antibody Neuropathy: a Phase II Italian Multicenter Clinical Trial (MAZINGA)
Lead sponsor
Azienda Ospedaliera di Padova
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2026
Completion date
March 31, 2031
Enrollment
50 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anti-mag igm-associated demyelinating polyneuropathy